

*MALAYSIAN UROLOGICAL ASSOCIATION*



**YOU ARE  
CORDIALLY  
INVITED**



**LIVE HYBRID CME TALK**

CPD Points will be provided



LIVE HYBRID CME TALK

# ADVANCEMENT IN PROSTATE CANCER MANAGEMENT

CHAIRPERSON  
DATO' DR ROHAN MALEK,

## SPEAKERS



**PROF DR EDMUND CHIONG**

Phd, MBBS (NUS), FRCSEd (UK), FRCSI  
(Ireland), FAMS (Sg)



**DR NEAL SHORE**  
MD, FACS



**PROF DR ONG TENG AIK**

FRCs (Urology) (UK), FRCSI (Ire), AM  
(Mal), MS (UM), FEBU, FRCs(Urology),  
FRCSI, MBBS (UM), MBBS(MAL), MS(Mal)



Friday, 04 MARCH 2022  
19:00 — 21:00



6TH FLOOR,  
CENTRAL BALLROOM  
KL HILTON

TO RSVP  
+6012-298 7857 WAI MING  
+6014-338 6506 JET



CPD Points will be provided



LIVE HYBRID CME TALK

# ADVANCEMENT IN PROSTATE CANCER MANAGEMENT

- 6.00pm Arrival of Guests (light meals will be provided)
- 7.00pm Welcome Address by Dato' Dr Rohan Malek
- 7.05pm The role of Eligard® - THE ASIAN MEN PERSPECTIVES  
(Review of Eligant Study, Part 1)  
by Assoc Prof Dr Edmund Chiong
- 7.20pm The role of Eligard® - THE ASIAN MEN PERSPECTIVES  
(Review of Eligant Study, Part 2)  
by Prof Dr Ong Teng Aik

## **Keynote Speaker:**

- 7.35pm The Advancement in the Management of Prostate  
Cancer with Androgen Deprivation Therapy  
by Dr Neal Shore
- 8.15pm Q&A
- 8.30pm Adjourn for Dinner

CPD Points will be provided

# SPEAKERS BIO



## DR NEAL SHORE

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He is the Chief Surgical Officer and Head of Urology, Genesis Care, US. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Boards of: Duke Global Health Institute, Society of Urologic Oncology, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. He serves as the National Urology Research Director for Genesis Care, US. He is the Co-Chair, AUA International Prostate Cancer Forum and has served on the AUA Male Health and AUA Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal of Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial



## PROF DR EDMUND CHIONG

A/Prof Edmund Chiong graduated with the degrees of Bachelor of Medicine and Surgery from the National University of Singapore (NUS) in 1995. He obtained postgraduate qualifications (Fellow of the Royal College of Surgeons of Edinburgh and Fellow of the Royal College of Surgeons in Ireland) in Surgery (in 2000) and completed his Urology specialist training in Singapore. A/Prof Chiong subsequently completed a 2-year clinical fellowship program in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He is also certified by the Society of Urologic Oncology, USA. A/Prof Chiong's subspecialty interests include managing and performing surgery for prostate cancers, bladder cancers, kidney cancers, testes cancers, penile cancers, and performing DaVinci robotic surgery. A/Prof Chiong also manages general urologic diseases and is a kidney transplant surgeon with the Ministry of Health's renal transplantation team. Apart from clinical practice, A/Prof Chiong is also actively involved in both clinical and laboratory research. His research interests include investigating immunotherapy, gene therapy and targeted therapy for bladder cancer, and diagnostic modalities and new therapies for urologic malignancies. He has minor interests in investigating urinary tract infections, and medical device innovation.



## PROF DR ONG TENG AIK

Prof Dr Ong was born and educated in Kuala Lumpur. He graduated with MBBS from the University of Malaya in 1995. He served for 15 years in various hospitals in Kuala Lumpur (HKL, UHKL), Sabah and Sarawak before joining UMMC in 2010. Prof Dr Ong obtained the Fellowship of the Royal College of Surgeons in Ireland in 2000 and the Master of Surgery in 2002. After 2002, he served as a senior lecturer and then Associate Professor in University of Malaysia Sarawak (UNIMAS). He received the Excellence Award in Service from UNIMAS in 2009. Prof Dr Ong had most of his urology training in Sarawak General Hospital, Kuching, Sarawak, under senior urologists Dr Teh Guan Chou and Dr Clarence Lei. In the same year, Prof Dr Ong won the British Journal of Urology International (BJUI) scholarship to further his training in the United Kingdom. He also published a paper in BJUI on retroperitoneal lymph node dissection with Dr Timothy Christmas, a renowned surgeon of the Charing Cross Hospital, London. For research, Prof Dr Ong focuses on uro-oncology. Currently, Prof Dr Ong serves as the president of Malaysian Urology Association.

CPD Points will be provided